aluates Reports

$ 0.0

Automative

Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Research Report 2025

Published Date: April 2025

Report Code: QYRE-Auto-14H13294

Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Research Report 2023

BUY CHAPTERS

Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Research Report 2025

Code: QYRE-Auto-14H13294

Report

April 2025

Pages:90

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Teva Pharmaceutical Industries

Genentech Inc

Cephalon

Amgen Inc

Sanofi

Astrazeneca plc

Roche

Koninklijke DSM

Novartis

GSK

Baxter International

Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Eosinophilic Granulomatosis with Polyangiitis Treatment Market

The global market for Eosinophilic Granulomatosis with Polyangiitis Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare autoimmune disease that affects small and medium-sized blood vessels and is characterized by eosinophilic inflammation. EGPA can involve multiple organ systems, including the skin, lungs, heart, nerves, and gastrointestinal tract. Treatment for EGPA typically involves a combination of medications to suppress the immune system, manage inflammation, and alleviate specific symptoms. The choice of treatment may depend on the severity of the disease and the organs affected.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Eosinophilic Granulomatosis with Polyangiitis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Eosinophilic Granulomatosis with Polyangiitis Treatment.

The Eosinophilic Granulomatosis with Polyangiitis Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Eosinophilic Granulomatosis with Polyangiitis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Eosinophilic Granulomatosis with Polyangiitis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Eosinophilic Granulomatosis with Polyangiitis Treatment Market Report

Report Metric	Details
Report Name	Eosinophilic Granulomatosis with Polyangiitis Treatment Market
CAGR	5%
Segment by Type	Steroids Immunosuppressant Biologics Immune Globulins
Segment by Application	Oral Intravenous Intramuscular
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Genentech, Roche, Cephalon, Teva Pharmaceutical Industries, Amgen, Sanofi, Koninklijke DSM, AstraZeneca, Novartis, GSK, Baxter International
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Eosinophilic Granulomatosis with Polyangiitis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Eosinophilic Granulomatosis with Polyangiitis Treatment Market report?

Ans: The main players in the Eosinophilic Granulomatosis with Polyangiitis Treatment Market are Genentech, Roche, Cephalon, Teva Pharmaceutical Industries, Amgen, Sanofi, Koninklijke DSM, AstraZeneca, Novartis, GSK, Baxter International

What are the Application segmentation covered in the Eosinophilic Granulomatosis with Polyangiitis Treatment Market report?

Ans: The Applications covered in the Eosinophilic Granulomatosis with Polyangiitis Treatment Market report are Oral, Intravenous, Intramuscular

What are the Type segmentation covered in the Eosinophilic Granulomatosis with Polyangiitis Treatment Market report?

Ans: The Types covered in the Eosinophilic Granulomatosis with Polyangiitis Treatment Market report are Steroids, Immunosuppressant, Biologics, Immune Globulins

Recommended Reports

Autoimmune Diseases

Rare Disease Treatments

Respiratory Disorders

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Steroids

1.2.3 Immunosuppressant

1.2.4 Biologics

1.2.5 Immune Globulins

1.3 Market by Application

1.3.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Oral

1.3.3 Intravenous

1.3.4 Intramuscular

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Perspective (2020-2031)

2.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Growth Trends by Region

2.2.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Eosinophilic Granulomatosis with Polyangiitis Treatment Historic Market Size by Region (2020-2025)

2.2.3 Eosinophilic Granulomatosis with Polyangiitis Treatment Forecasted Market Size by Region (2026-2031)

2.3 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Dynamics

2.3.1 Eosinophilic Granulomatosis with Polyangiitis Treatment Industry Trends

2.3.2 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Drivers

2.3.3 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Challenges

2.3.4 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Eosinophilic Granulomatosis with Polyangiitis Treatment Players by Revenue

3.1.1 Global Top Eosinophilic Granulomatosis with Polyangiitis Treatment Players by Revenue (2020-2025)

3.1.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Players (2020-2025)

3.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue

3.4 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Concentration Ratio

3.4.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in 2024

3.5 Global Key Players of Eosinophilic Granulomatosis with Polyangiitis Treatment Head office and Area Served

3.6 Global Key Players of Eosinophilic Granulomatosis with Polyangiitis Treatment, Product and Application

3.7 Global Key Players of Eosinophilic Granulomatosis with Polyangiitis Treatment, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Eosinophilic Granulomatosis with Polyangiitis Treatment Breakdown Data by Type

4.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Historic Market Size by Type (2020-2025)

4.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecasted Market Size by Type (2026-2031)

5 Eosinophilic Granulomatosis with Polyangiitis Treatment Breakdown Data by Application

5.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Historic Market Size by Application (2020-2025)

5.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size (2020-2031)

6.2 North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025)

6.4 North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size (2020-2031)

7.2 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025)

7.4 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size (2020-2031)

8.2 Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (2020-2025)

8.4 Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size (2020-2031)

9.2 Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025)

9.4 Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size (2020-2031)

10.2 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025)

10.4 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Genentech

11.1.1 Genentech Company Details

11.1.2 Genentech Business Overview

11.1.3 Genentech Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction

11.1.4 Genentech Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

11.1.5 Genentech Recent Development

11.2 Roche

11.2.1 Roche Company Details

11.2.2 Roche Business Overview

11.2.3 Roche Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction

11.2.4 Roche Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

11.2.5 Roche Recent Development

11.3 Cephalon

11.3.1 Cephalon Company Details

11.3.2 Cephalon Business Overview

11.3.3 Cephalon Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction

11.3.4 Cephalon Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

11.3.5 Cephalon Recent Development

11.4 Teva Pharmaceutical Industries

11.4.1 Teva Pharmaceutical Industries Company Details

11.4.2 Teva Pharmaceutical Industries Business Overview

11.4.3 Teva Pharmaceutical Industries Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction

11.4.4 Teva Pharmaceutical Industries Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

11.4.5 Teva Pharmaceutical Industries Recent Development

11.5 Amgen

11.5.1 Amgen Company Details

11.5.2 Amgen Business Overview

11.5.3 Amgen Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction

11.5.4 Amgen Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

11.5.5 Amgen Recent Development

11.6 Sanofi

11.6.1 Sanofi Company Details

11.6.2 Sanofi Business Overview

11.6.3 Sanofi Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction

11.6.4 Sanofi Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

11.6.5 Sanofi Recent Development

11.7 Koninklijke DSM

11.7.1 Koninklijke DSM Company Details

11.7.2 Koninklijke DSM Business Overview

11.7.3 Koninklijke DSM Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction

11.7.4 Koninklijke DSM Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

11.7.5 Koninklijke DSM Recent Development

11.8 AstraZeneca

11.8.1 AstraZeneca Company Details

11.8.2 AstraZeneca Business Overview

11.8.3 AstraZeneca Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction

11.8.4 AstraZeneca Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

11.8.5 AstraZeneca Recent Development

11.9 Novartis

11.9.1 Novartis Company Details

11.9.2 Novartis Business Overview

11.9.3 Novartis Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction

11.9.4 Novartis Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

11.9.5 Novartis Recent Development

11.10 GSK

11.10.1 GSK Company Details

11.10.2 GSK Business Overview

11.10.3 GSK Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction

11.10.4 GSK Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

11.10.5 GSK Recent Development

11.11 Baxter International

11.11.1 Baxter International Company Details

11.11.2 Baxter International Business Overview

11.11.3 Baxter International Eosinophilic Granulomatosis with Polyangiitis Treatment Introduction

11.11.4 Baxter International Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

11.11.5 Baxter International Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Teva Pharmaceutical Industries

Genentech Inc

Cephalon

Amgen Inc

Sanofi

Astrazeneca plc

Roche

Koninklijke DSM

Novartis

GSK

Baxter International

List of Tables

Table 1. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Steroids

Table 3. Key Players of Immunosuppressant

Table 4. Key Players of Biologics

Table 5. Key Players of Immune Globulins

Table 6. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Region (2020-2025)

Table 10. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Region (2026-2031)

Table 12. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Trends

Table 13. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Drivers

Table 14. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Challenges

Table 15. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Restraints

Table 16. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Players (2020-2025)

Table 18. Global Top Eosinophilic Granulomatosis with Polyangiitis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment as of 2024)

Table 19. Ranking of Global Top Eosinophilic Granulomatosis with Polyangiitis Treatment Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Eosinophilic Granulomatosis with Polyangiitis Treatment, Headquarters and Area Served

Table 22. Global Key Players of Eosinophilic Granulomatosis with Polyangiitis Treatment, Product and Application

Table 23. Global Key Players of Eosinophilic Granulomatosis with Polyangiitis Treatment, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Type (2020-2025)

Table 27. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Type (2026-2031)

Table 29. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Application (2020-2025)

Table 31. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Application (2026-2031)

Table 33. North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 48. Genentech Company Details

Table 49. Genentech Business Overview

Table 50. Genentech Eosinophilic Granulomatosis with Polyangiitis Treatment Product

Table 51. Genentech Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)

Table 52. Genentech Recent Development

Table 53. Roche Company Details

Table 54. Roche Business Overview

Table 55. Roche Eosinophilic Granulomatosis with Polyangiitis Treatment Product

Table 56. Roche Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)

Table 57. Roche Recent Development

Table 58. Cephalon Company Details

Table 59. Cephalon Business Overview

Table 60. Cephalon Eosinophilic Granulomatosis with Polyangiitis Treatment Product

Table 61. Cephalon Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)

Table 62. Cephalon Recent Development

Table 63. Teva Pharmaceutical Industries Company Details

Table 64. Teva Pharmaceutical Industries Business Overview

Table 65. Teva Pharmaceutical Industries Eosinophilic Granulomatosis with Polyangiitis Treatment Product

Table 66. Teva Pharmaceutical Industries Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)

Table 67. Teva Pharmaceutical Industries Recent Development

Table 68. Amgen Company Details

Table 69. Amgen Business Overview

Table 70. Amgen Eosinophilic Granulomatosis with Polyangiitis Treatment Product

Table 71. Amgen Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)

Table 72. Amgen Recent Development

Table 73. Sanofi Company Details

Table 74. Sanofi Business Overview

Table 75. Sanofi Eosinophilic Granulomatosis with Polyangiitis Treatment Product

Table 76. Sanofi Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)

Table 77. Sanofi Recent Development

Table 78. Koninklijke DSM Company Details

Table 79. Koninklijke DSM Business Overview

Table 80. Koninklijke DSM Eosinophilic Granulomatosis with Polyangiitis Treatment Product

Table 81. Koninklijke DSM Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)

Table 82. Koninklijke DSM Recent Development

Table 83. AstraZeneca Company Details

Table 84. AstraZeneca Business Overview

Table 85. AstraZeneca Eosinophilic Granulomatosis with Polyangiitis Treatment Product

Table 86. AstraZeneca Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)

Table 87. AstraZeneca Recent Development

Table 88. Novartis Company Details

Table 89. Novartis Business Overview

Table 90. Novartis Eosinophilic Granulomatosis with Polyangiitis Treatment Product

Table 91. Novartis Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)

Table 92. Novartis Recent Development

Table 93. GSK Company Details

Table 94. GSK Business Overview

Table 95. GSK Eosinophilic Granulomatosis with Polyangiitis Treatment Product

Table 96. GSK Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)

Table 97. GSK Recent Development

Table 98. Baxter International Company Details

Table 99. Baxter International Business Overview

Table 100. Baxter International Eosinophilic Granulomatosis with Polyangiitis Treatment Product

Table 101. Baxter International Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025) & (US$ Million)

Table 102. Baxter International Recent Development

Table 103. Research Programs/Design for This Report

Table 104. Key Data Information from Secondary Sources

Table 105. Key Data Information from Primary Sources

Table 106. Authors List of This Report

List of Figures

Figure 1. Eosinophilic Granulomatosis with Polyangiitis Treatment Picture

Figure 2. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Type: 2024 VS 2031

Figure 4. Steroids Features

Figure 5. Immunosuppressant Features

Figure 6. Biologics Features

Figure 7. Immune Globulins Features

Figure 8. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Application: 2024 VS 2031

Figure 10. Oral Case Studies

Figure 11. Intravenous Case Studies

Figure 12. Intramuscular Case Studies

Figure 13. Eosinophilic Granulomatosis with Polyangiitis Treatment Report Years Considered

Figure 14. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Region: 2024 VS 2031

Figure 17. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Players in 2024

Figure 18. Global Top Eosinophilic Granulomatosis with Polyangiitis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment as of 2024)

Figure 19. The Top 10 and 5 Players Market Share by Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in 2024

Figure 20. North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Country (2020-2031)

Figure 22. United States Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Country (2020-2031)

Figure 26. Germany Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Region (2020-2031)

Figure 34. China Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Country (2020-2031)

Figure 42. Mexico Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Country (2020-2031)

Figure 46. Turkey Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Genentech Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

Figure 50. Roche Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

Figure 51. Cephalon Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

Figure 52. Teva Pharmaceutical Industries Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

Figure 53. Amgen Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

Figure 54. Sanofi Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

Figure 55. Koninklijke DSM Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

Figure 56. AstraZeneca Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

Figure 57. Novartis Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

Figure 58. GSK Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

Figure 59. Baxter International Revenue Growth Rate in Eosinophilic Granulomatosis with Polyangiitis Treatment Business (2020-2025)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Eosinophilic Granulomatosis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Granulomatosis with Polyangiitis Drug Market Research Report 2025

Eosinophilic Esophagitis Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Microscopic Polyangiitis MPA Treatment Market Research Report 2025

Global Churg Strauss Syndrome Market Research Report 2024

Global Medicines for Eosinophilic Asthma Treatment Market Research Report 2025

Global Retinal Vasculitis Treatment Market Research Report 2025

Chronic Granulomatous Disease CGD Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Severe Eosinophilic Asthma Treatment Market Research Report 2024

Erythropoietic Protoporphyria EPP Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Giant Cell Arteritis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Lupus Erythematosus Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Optic Neuritis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Goodpasture Syndrome Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Eosinophilic Asthma Treatment Market Research Report 2025

Hypersensitivity Pneumonitis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Drugs for Blau Syndrome Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Eosinophilia Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Interventional Pulmonary Diseases Related to Chronic Obstructive Pulmonary Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Insulin Coolers Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-19Z7671

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Ossicular Prostheses Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-10V14317

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Defibrillator Accessories Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-10O5919

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Septicemia Diagnostic Testing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-4I19963

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions